Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908236 | 0.91 | SLC2A1 (0.40) | SLC2A1MMP9MMP8MMP13LMNA | |
| SCHEMBL533740 | 0.89 | MMP9 (0.38) | SLC2A1MMP9MMP8MMP13TDP1 | |
| SCHEMBL3504560 | 0.83 | FAAH (0.41) | MMP9MMP8MMP13LMNAFAAH | |
| SCHEMBL533775 | 0.81 | MMP9 (0.39) | MMP9MMP8MMP13LMNAFAAH | |
| SCHEMBL13164734 | 0.81 | MAPK1 (0.47) | MMP9MMP8MMP13LMNAFAAH | |
| SCHEMBL15908216 | 0.80 | MMP9 (0.38) | SLC2A1MMP9MMP8MMP13LMNA | |
| SCHEMBL2016511 | 0.78 | NPC1 (0.42) | LMNANR5A1S1PR1S1PR3S1PR5 | |
| SCHEMBL533766 | 0.77 | LMNA (0.43) | LMNANR5A1LTA4HS1PR1S1PR3 | |
| SCHEMBL13837524 | 0.77 | CNR1 (0.43) | TDP1 | |
| SCHEMBL13505329 | 0.76 | CNR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169187-B2 | Method of making peptides using diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2015-10-27 | — | — | US | claimed |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC (JP) | 2014-07-31 | — | — | US | claimed |
| US-8722934-B2 | Diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2014-05-13 | — | — | US | claimed |
| EP-2415745-A1 | DIPHENYLMETHANE COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | claimed |
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-09-30 | — | — | US | claimed |
| US-12351601-B2 | Method for producing peptide continuously | AJINOMOTO CO., INC. (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025122535-A2 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | AJINOMOTO CO., INC. (JP) | 2022-02-10 | — | — | US | disclosed |
| WO-2020218497-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | 味の素株式会社 | 2020-10-29 | — | — | WO | disclosed |
| EP-3412689-B1 | HYDROGENATED BLOCK-COPOLYMER HAVING ACID ANHYDRIDE GROUP AND USE THEREOF | ZEON CORP (JP) | 2020-10-14 | — | — | EP | disclosed |
| US-20190203035-A1 | BLOCK-COPOLYMER HYDRIDE HAVING ACID ANHYDRIDE GROUP AND USE THEREOF | ZEON CORPORATION (JP) | 2019-07-04 | — | — | US | disclosed |
| US-9169187-B2 | Method of making peptides using diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | AJINOMOTO CO., INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC (JP) | 2014-07-31 | — | — | US | disclosed |
| US-8722934-B2 | Diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8722934-B2 | Diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2415745-A1 | DIPHENYLMETHANE COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, DNPEP, QPCTL | SLC2A1 4330/4885MMP9 4585/4885MMP8 4199/4885 |
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | SLC2A1 4401/4885MMP9 2781/4885MMP8 3364/4885 |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | VIP, NPPA, NGLY1 | SLC2A1 4042/4885MMP9 2268/4885MMP8 2478/4885 |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, VIP, CCKBR | SLC2A1 3858/4885MMP9 3657/4885MMP8 4073/4885 |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | ESD, HM13, FURIN | SLC2A1 4145/4885MMP9 289/4885MMP8 1035/4885 |
| US-12351601-B2 | Method for producing peptide continuously | VIP, NPPA, NGLY1 | SLC2A1 4042/4885MMP9 2268/4885MMP8 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.